Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2021

Open Access 01-12-2021 | Acute Kidney Injury | Research

Galectin-3 in septic acute kidney injury: a translational study

Authors: Haibing Sun, Huiping Jiang, Amity Eliaz, John A. Kellum, Zhiyong Peng, Isaac Eliaz

Published in: Critical Care | Issue 1/2021

Login to get access

Abstract

Background

Galectin-3 (Gal-3) is a pleiotropic glycan-binding protein shown to be involved in sepsis and acute kidney injury (AKI). However, its role has never been elucidated in sepsis-associated AKI (S-AKI). We aimed to explore Gal-3’s role and its potential utility as a therapeutic target in S-AKI.

Methods

In 57 patients admitted to the intensive care unit (ICU) with sepsis, serum Gal-3 was examined as a predictor of ICU mortality and development of AKI. In a rat model of S-AKI induced by cecal ligation and puncture (CLP), 7-day mortality and serum Gal-3, Interleukin-6 (IL-6), and creatinine were examined at 2, 8, and 24 hours (h) post-CLP. Two experimental groups received the Gal-3 inhibitor modified citrus pectin (P-MCP) at 400 mg/kg/day and 1200 mg/kg/day, while the control group received water only (n = 18 in each group).

Results

Among 57 patients, 27 developed AKI and 8 died in the ICU. Serum Gal-3 was an independent predictor of AKI (OR = 1.2 [95% CI 1.1–1.4], p = 0.01) and ICU mortality (OR = 1.4 [95% CI 1.1–2.2], p = 0.04) before and after controlling for age, AKI, and acute physiology and chronic health evaluation (APACHE II) score. In the CLP rat experiment, serum Gal-3 peaked earlier than IL-6. Serum Gal-3 was significantly lower in both P-MCP groups compared to control at 2 h post-CLP (400 mg: p = 0.003; 1200 mg: p = 0.002), and IL-6 was significantly lower in both P-MCP groups at all time points with a maximum difference at 24 h post-CLP (400 mg: p = 0.015; 1200 mg: p = 0.02). In the Gal-3 inhibitor groups, 7-day mortality was significantly reduced from 61% in the control group to 28% (400 mg P-MCP: p = 0.03) and 22% (1200 mg P-MCP: p = 0.001). Rates of AKI per RIFLE criteria were significantly reduced from 89% in the control group to 44% in both P-MCP groups (400 mg: p = 0.007; 1200 mg: p = 0.007).

Conclusions

This translational study demonstrates the importance of Gal-3 in the pathogenesis of S-AKI, and its potential utility as a therapeutic target.

Graphic abstract

Literature
1.
Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813–8.PubMedCrossRef
2.
Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. CJASN. 2007;2:431–9.PubMedCrossRef
3.
Bouchard J, Acharya A, Cerda J, Maccariello ER, Madarasu RC, Tolwani AJ, et al. A prospective international multicenter study of AKI in the intensive care unit. CJASN. 2015;10:1324–31.PubMedCrossRefPubMedCentral
4.
Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41:1411–23.PubMedCrossRef
5.
Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200–1.PubMedPubMedCentralCrossRef
6.
7.
Mehta RL, Bouchard J, Soroko SB, Ikizler TA, Paganini EP, Chertow GM, et al. Sepsis as a cause and consequence of acute kidney injury: program to improve care in acute renal disease. Intensive Care Med. 2011;37:241–8.PubMedCrossRef
8.
Tandukar S, Palevsky PM. Continuous renal replacement therapy: who, when, why, and how. Chest. 2019;155(3):626–38.PubMedCrossRef
9.
Singbartl K, Formeck CL, Kellum JA. Kidney-immune system crosstalk in AKI. Semin Nephrol. 2019;39:96–106.PubMedCrossRef
10.
Tanaka T, Narazaki M. Kishimoto T immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8:959–70.PubMedCrossRef
11.
Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11:R49.PubMedPubMedCentralCrossRef
12.
Kellum JA, Kon L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167(15):1655–63.PubMedPubMedCentralCrossRef
13.
Wu HP, Chen CK, Chung K, Tseng JC, Hua CC, Liu YC, et al. Serial cytokine levels in patients with severe sepsis. Inflamm Res. 2009;58:385–93.PubMedCrossRef
14.
Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, et al. Multiplex cytokine profiling in patients with sepsis. APMIS. 2011;119:155–63.PubMedCrossRef
15.
Kellum JA, Pike F, Yealy DM, Huang DT, Shapiro NI, Angus DC, et al. Relationship between alternative resuscitation strategies, host response and injury biomarkers, and outcome in septic shock. Critical Care Med. 2017;45(3):438–45.CrossRef
16.
17.
Buckley LF, Wohlford GF, Ting C, Alahmed A, Van Tassell BW, Abbate A, et al. Role for anti-cytokine therapies in severe coronavirus disease 2019. Critical Care Explor. 2020;2:e0178.CrossRef
18.
Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616–35.PubMedCrossRef
19.
Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160–71.PubMedCrossRef
20.
ten Oever J, Giamarellos-Bourboulis E, Van De Veerdonk F, Stelma F, Simon A, Janssen M, et al. Circulating galectin-3 in infections and non-infectious inflammatory diseases. Eur J Clin Microbiol Infect Dis. 2013;32:1605–10.PubMedCrossRef
21.
Mueller T, Leitner I, Egger M, Haltmayer M, Dieplinger B. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin Chim Acta. 2015;445:155–60.PubMedCrossRef
22.
Dieplinger B, Egger M, Leitner I, Firlinger F, Poelz W, Lenz K, et al. Interleukin 6, galectin 3, growth differentiation factor 15, and soluble ST2 for mortality prediction in critically ill patients. J Crit Care. 2016;34:38–45.PubMedCrossRef
23.
24.
Drechsler C, Delgado G, Wanner C, Blouin K, Pilz S, Tomaschitz A, et al. Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies. JASN. 2015;26:2213–21.PubMedCrossRefPubMedCentral
25.
Rebholz CM, Selvin E, Liang M, Ballantyne CM, Hoogeveen RC, Aguilar D, et al. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int. 2018;93:252–9.PubMedCrossRef
26.
Kim H, Hur M, Moon HW, Yun YM, Di Somma S. Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. Ann Intensive Care. 2017;7:27.PubMedPubMedCentralCrossRef
27.
von Ballmoos MW, Likosky DS, Rezaee M, Lobdell K, Alam S, Parker D, et al. Elevated preoperative galectin-3 is associated with acute kidney injury after cardiac surgery. BMC Nephrol. 2018;19:280.CrossRef
28.
Prud’homme M, Coutrot M, Michel T, Boutin L, Genest M, Poirier F, et al. Acute kidney injury induces remote cardiac damage and dysfunction through the galectin-3 pathway. JACC Basic Transl Sci. 2019;4:717–32.PubMedPubMedCentralCrossRef
29.
Mishra BB, Li Q, Steichen AL, Binstock BJ, Metzger DW, Teale JM, et al. Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS ONE. 2013;8:e59616.PubMedPubMedCentralCrossRef
30.
Ferreira RG, Rodrigues LC, Nascimento DC, Kanashiro A, Melo PH, Borges VF, et al. Galectin-3 aggravates experimental polymicrobial sepsis by impairing neutrophil recruitment to the infectious focus. J Infect. 2018;77:391–7.PubMedCrossRef
31.
Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008;172:288–98.PubMedPubMedCentralCrossRef
32.
Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy11 antibodies. J Pathol. 1999;187:481–9.PubMedCrossRef
33.
Nishiyama J, Kobayashi S, Ishida A, Nakabayashi I, Tajima O, Miura S, et al. Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol. 2000;157:815–23.PubMedPubMedCentralCrossRef
34.
Dang Z, MacKinnon A, Marson LP, Sethi T. Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation. 2012;93:477–84.PubMedCrossRef
35.
Fernandes Bertocchi AP, Campanhole G, Wang PHM, Gonçalves GM, Damião MJ, Cenedeze MA, et al. A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int. 2008;21:999–1007.PubMedCrossRef
36.
Kolatsi-Joannou M, Price KL. Winyard, PJ Long, DA Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS ONE. 2011;6(e1868):3.
37.
Frenay A-RS, Yu L, van der Velde AR, Vreeswijk-Baudoin I, López-Andrés N, van Goor H, et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Renal Physiol. 2015;308:F500-F509.
38.
Martínez-Martínez E, Ibarrola J, Fernández-Celis A, Calvier L, Leroy C, Cachofeiro V, et al. Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats. J Hypertens. 2018;36:368–76.PubMedCrossRef
39.
Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 2015;3:59–67.PubMedCrossRef
40.
Zhang M, Gu Y, Wang H, Zhu P, Liu X, Wu J. Valsartan attenuates cardiac and renal hypertrophy in rats with experimental cardiorenal syndrome possibly through down-regulating galectin-3 signaling. Eur Rev Med Pharmacol Sci. 2016;20:345–54.PubMed
41.
Martinez-Martinez E, Ibarrola J, Calvier L, Fernandez-Celis A, Leroy C, Cachofeiro V, et al. Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage. PLoS ONE. 2016;11:e0166272.PubMedPubMedCentralCrossRef
42.
Li HY, Yang S, Li JC, Fen, JX. Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity. Biosci Rep. 2018;38:BSR20181803.
43.
Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:775–87.PubMedPubMedCentralCrossRef
44.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.PubMedCrossRef
45.
Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdman EA, Goldstein SL, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
46.
47.
Peng ZY, Wang HZ, Srisawat N, Wen X, Rimmelé T, Bishop J, et al. Bactericidal antibiotics temporarily increase inflammation and worsen acute kidney injury in experimental sepsis. Crit Care Med. 2012;40:538–43.PubMedPubMedCentralCrossRef
48.
Zhou F, Peng ZY, Bishop JV, Cove ME, Singbartl K, Kellum JA. Effects of fluid resuscitation with 09% saline versus a balanced electrolyte solution on acute kidney injury in a rat model of sepsis. Crit Care Med. 2014;42:e270–8.PubMedPubMedCentralCrossRef
49.
Zou KH, O’Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007;115:654–7.PubMedCrossRef
50.
Huang YT, Lai MY, Kan WC, Shiao CC. Independent Predictive Ability of Procalcitonin of Acute Kidney Injury among Critically Ill Patients. J Clin Med. 2020;9(6):1939.PubMedCentralCrossRef
51.
Chun K, Chung W, Kim AJ, Hyunsook K, Han R, Jae HC, et al. Association between acute kidney injury and serum procalcitonin levels and their diagnostic usefulness in critically ill patients. Sci Rep. 2019;9:4777.PubMedPubMedCentralCrossRef
52.
Dai X, Zeng Z, Fu C, Zhang S, Cai Y, Chen Z. Diagnostic value of neutrophil gelatinase-associated lipocalin, cystatin C, and soluble triggering receptor expressed on myeloid cells-1 in critically ill patients with sepsis-associated acute kidney injury. Crit Care. 2015;19(1):223.PubMedPubMedCentralCrossRef
53.
Desmedt V, Desmedt S, Delanghe JR, Speeckaert R, Speeckaert MM. Galectin-3 in renal pathology: more than just an innocent bystander? Am J Nephrol. 2016;43:305–17.PubMedCrossRef
54.
Garcia-Revilla J, Deierborg T, Venero JL, Boza-Serrano A. Hyperinflammation and fibrosis in severe COVID-19 patients: Galectin-3, a target molecule to consider. Front Immunol. 2020;11:2069.PubMedPubMedCentralCrossRef
Metadata
Title
Galectin-3 in septic acute kidney injury: a translational study
Authors
Haibing Sun
Huiping Jiang
Amity Eliaz
John A. Kellum
Zhiyong Peng
Isaac Eliaz
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2021
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-021-03538-0

Other articles of this Issue 1/2021

Critical Care 1/2021 Go to the issue

Letter

Utility of AI models in critical care: union of man and the machine

Research

The immune modulatory effects of mitochondrial transplantation on cecal slurry model in rat

Research Letter

Role of MR-proADM in the risk stratification of COVID-19 patients assessed at the triage of the Emergency Department

Research Letter

Effects of levosimendan on occurrence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a case–control study

Research

Systematic early versus late mobilization or standard early mobilization in mechanically ventilated adult ICU patients: systematic review and meta-analysis

Research Letter

Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave?